Bloomberg Intelligence's Sam Fazeli discusses AbbVie's $10.9 billion acquisition of Apogee Therapeutics. The deal enhances AbbVie's presence in dermatology by adding treatments for atopic dermatitis, commonly known as eczema, to its portfolio. He speaks on "Bloomberg Open Interest." (Source: Bloomberg)
Bloomberg Intelligence's Sam Fazeli discusses AbbVie's $10.9 billion acquisition of Apogee Therapeutics. The deal enhances AbbVie's presence in dermatology by adding treatments for atopic dermatitis, commonly known as eczema, to its portfolio. He speaks on "Bloomberg Open Interest." (Source: Bloomberg)
<iframe src="https://statesidedaily.com/embed/cluster/549ba7b8fc28bcb28016268f81adc684790b090b" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="AbbVie to Buy Apogee Therapeutics for $10.9 Billion"></iframe>
